Preclinical assessment of a new recombinant ADAMTS‐13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura

Preclinical assessment of a new recombinant ADAMTS‐13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura

A Kopić, K Benamara, C Piskernik… - … of Thrombosis and …, 2016 - Wiley Online Library

... antigen ELISA. ADAMTS-13 proteolytic activity was determined by use of the synthetic
fluorogenic FRETS-VWF73 minimal peptide substrate (Peptide Institute, Osaka,
Japan), essentially as described previously [21]. Samples ...

Eva He

eva@pepmic.com

Pepmic Co., Ltd

www.pepmic.com